AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Immunocore Holdings Ltd (NASDAQ:IMCR)
31.685 USD
-0.335 1.046%Sponsored Reports
Loading...
| Previous Close (in USD) | 32.02 |
|---|---|
| Change | -0.335 1.046% |
| 52 W H/L (in USD) | 76.980/41.010 |
| EBITDA (in USD) | -68.191M |
| PE Ratio | -- |
| Volume | 70993 |
| Diluted Eps TTM | -1.55 |
| Total Assets (in USD) | 597.001M |
|---|---|
| Total Liabilities (in USD) | 228.158M |
| Revenue TTM (in USD) | 265.271M |
| Cash (in USD) | 442.626M |
| Market Cap (in USD) | 2,303.034 M |
| Revenue Per Share TTM | 5.379 |
| Gross Profit TTM (in USD) | 54.113M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Immunocore Holdings Ltd
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Employees: 497
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Bahija Jallal Ph.D. | CEO & Director | 1962 |
| 2. | Mr. Brian R. Di Donato M.B.A. | CFO & Head of Strategy | 1967 |
| 3. | Ms. Annelise Vuidepot Ph.D. | CTO and Head of Pipeline & Platform Research | NA |
| 4. | Clayton Robertson | Head of Investor Relations | NA |
| 5. | Ms. Lily Hepworth | Gen. Counsel & Company Sec. | NA |
| 6. | Ms. Amy Judge-Prein | Chief Compliance Officer | NA |
| 7. | Mr. Sébastien Desprez | Head of Communications | NA |
| 8. | Ms. Tina St. Leger | Chief HR Officer | 1969 |
| 9. | Dr. David Berman M.D., Ph.D. | Head of R&D | 1971 |
| 10. | Ms. Debra Nielsen | Chief of Staff | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.070 1.581% | 68.76 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+2.420 3.640% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+2.740 0.618% | 442.99 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.606 0.500% | 521.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -44.145M | -140.928M | -87.36M | -126.189M | -88.178M |
| Minority Interest | - | - | - | - | - |
| Net Income | -41.224M | -131.523M | -74.093M | -103.931M | -71.63M |
| Selling General Administrative | 93.723M | 88.399M | 45.74M | 44.183M | 34.156M |
| Gross Profit | 143.283M | 26.52M | 30.114M | 25.669M | 23.654M |
| Reconciled Depreciation | 6.131M | 7.012M | 8.976M | 9.213M | 6.707M |
| Ebit | -39.607M | -135.162M | -86.193M | -118.32M | -87.654M |
| Ebitda | -36.453M | -135.115M | -75.447M | -107.714M | -80.947M |
| Depreciation And Amortization | 3.154M | 0.047M | 10.746M | 10.606M | 6.707M |
| Operating Income | -39.607M | -135.162M | -86.193M | -118.32M | -93.455M |
| Other Operating Expenses | 183.344M | 161.682M | 119.403M | 144.174M | 117.731M |
| Interest Expense | 7.692M | 5.813M | 3.109M | 3.796M | 0.842M |
| Tax Provision | -2.921M | -9.405M | -13.267M | -22.258M | -16.548M |
| Interest Income | 3.154M | 0.047M | 0.706M | 1.395M | 0.822M |
| Net Interest Income | -4.538M | -5.766M | -2.403M | -2.403M | -0.02M |
| Income Tax Expense | -2.921M | -9.405M | -13.267M | -22.258M | -16.548M |
| Total Revenue | 143.737M | 26.52M | 30.114M | 25.669M | 23.654M |
| Total Operating Expenses | 182.89M | 161.682M | 119.403M | 144.174M | 117.731M |
| Cost Of Revenue | 0.454M | - | - | - | - |
| Total Other Income Expense Net | -4.538M | -5.766M | -1.167M | -7.869M | 5.919M |
| Net Income From Continuing Ops | -41.224M | -131.523M | -74.093M | -103.931M | -71.63M |
| Net Income Applicable To Common Shares | -41.224M | -131.523M | -74.093M | -103.931M | -71.63M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 597.001M | 435.518M | 301.773M | 197.194M | 185.649M |
| Intangible Assets | - | 0M | - | - | - |
| Other Current Assets | 9.711M | 0.058M | 7.691M | 6.507M | 4.739M |
| Total Liab | 228.158M | 156.762M | 130.226M | 141.848M | 170.878M |
| Total Stockholder Equity | 368.843M | 278.756M | 171.547M | 55.346M | 14.771M |
| Other Current Liab | 114.32M | 0.051M | 0.039M | 47.172M | 5.127M |
| Common Stock | 0.135M | 0.097M | 0.088M | 0.001M | - |
| Capital Stock | 0.135M | 0.097M | 0.088M | 0.001M | 0M |
| Retained Earnings | -744.674M | -261.253M | -481.392M | -349.869M | -279.106M |
| Good Will | - | 0.41M | - | - | - |
| Other Assets | - | 11.582M | 7.51M | 7.219M | 6.488M |
| Cash | 442.626M | 332.539M | 237.886M | 129.716M | 73.966M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 139.021M | 83.09M | 61.18M | 54.998M | 84.513M |
| Current Deferred Revenue | 5.515M | 6.408M | 24.45M | - | 42.549M |
| Net Debt | -358.594M | -263.236M | -174.05M | -65.829M | -14.559M |
| Short Term Debt | 1.388M | 1.555M | 1.255M | 2.043M | 21.108M |
| Short Long Term Debt | - | - | - | - | 19.157M |
| Short Long Term Debt Total | 84.032M | 69.303M | 63.836M | 63.887M | 59.407M |
| Other Stockholder Equity | 1149.643M | 205.162M | 266.595M | 405.051M | 293.909M |
| Property Plant Equipment | - | 31.645M | 31.537M | 36.847M | 54.88M |
| Total Current Assets | 528.82M | 391.881M | 262.726M | 152.931M | 124.281M |
| Long Term Investments | - | 0.137M | 0.165M | 0.973M | 0.591M |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 61.435M | 58.399M | 24.84M | 23.215M | 50.049M |
| Long Term Debt | 48.011M | 39.5M | 37.226M | 36.654M | - |
| Inventory | 4.501M | 0.943M | -7.691M | - | - |
| Accounts Payable | 17.798M | 75.076M | 35.436M | 5.783M | 15.729M |
| Accumulated Other Comprehensive Income | -36.261M | 334.75M | 386.256M | 0.163M | -0.032M |
| Non Currrent Assets Other | 14.473M | 7.205M | 4.77M | 4.213M | 4.39M |
| Non Current Assets Total | 68.181M | 43.637M | 39.047M | 44.263M | 61.368M |
| Capital Lease Obligations | 36.021M | 29.803M | 26.61M | 27.233M | 40.25M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 0.193M | -0.367M | 0.467M | -4.137M | 27.451M |
| Total Cashflows From Investing Activities | 0.193M | -0.367M | 0.467M | -4.137M | 58.014M |
| Total Cash From Financing Activities | 138.226M | 276.252M | 115.941M | 55.127M | 0.101M |
| Net Income | -41.224M | -131.523M | -74.093M | -103.931M | -71.63M |
| Change In Cash | 114.312M | 146.03M | 55.75M | -50.419M | 41.502M |
| Begin Period Cash Flow | 287.295M | 175.117M | 73.966M | 124.385M | 82.883M |
| End Period Cash Flow | 401.607M | 321.147M | 129.716M | 73.966M | 124.385M |
| Total Cash From Operating Activities | -31.269M | -129.749M | -60.574M | -101.376M | -16.626M |
| Depreciation | 6.131M | 7.012M | 8.976M | 9.213M | 6.707M |
| Other Cashflows From Investing Activities | 2.385M | 0.564M | 2.866M | 0.057M | 34.1M |
| Dividends Paid | 0M | 0M | 0M | - | 0M |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | - | - |
| Other Cashflows From Financing Activities | 68.131M | 52.883M | 37.149M | -0.711M | 0.101M |
| Capital Expenditures | 2.197M | 1.008M | 3.074M | 4.276M | 3.537M |
| Change In Working Capital | -12.885M | -16.806M | -28.803M | -10.092M | 67.575M |
| Other Non Cash Items | -7.424M | -14.888M | 38.451M | 22.636M | -3.396M |
| Free Cash Flow | -33.466M | -130.757M | -63.648M | -105.652M | -20.163M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Health Care Inv | 1 year ago | 2897598 |
| 2. | T. Rowe Price Health Sciences | 1 year ago | 1213766 |
| 3. | Fidelity Growth Compy Commingled Pl O | 1 year ago | 936397 |
| 4. | Fidelity Growth Company Fund | 1 year ago | 701351 |
| 5. | Vanguard Explorer Inv | 1 year ago | 648221 |
| 6. | Polar Capital Biotech S Inc | 1 year ago | 500000 |
| 7. | T. Rowe Price New Horizons | 1 year ago | 409100 |
| 8. | US Small-Cap Growth II Equity Comp | 1 year ago | 409100 |
| 9. | Fiera SMID Growth | 1 year ago | 408386 |
| 10. | Fidelity Select Health Care | 1 year ago | 391904 |
| 11. | BlackRock Health Sciences Term Trust | 1 year ago | 381768 |
| 12. | Pictet-Biotech P USD | 1 year ago | 328601 |
| 13. | iShares Biotechnology ETF | 1 year ago | 307212 |
| 14. | T. Rowe Price All-Cap Opportunities Fund | 1 year ago | 306380 |
| 15. | T. Rowe Price US All-Cap Opp Eq Comp | 1 year ago | 306380 |
| 16. | UBS: US Equity Small Cap Growth | 1 year ago | 300160 |
| 17. | Wellington Global Hlthcr Eq USD G Ac | 1 year ago | 285617 |
| 18. | BNP Paribas Health Cr Innovtr Cl Cap | 1 year ago | 258328 |
| 19. | Fidelity Advisor Health Care I | 1 year ago | 248652 |
| 20. | T. Rowe Price Small-Cap Value | 1 year ago | 236300 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RTW INVESTMENTS, LLC | 1 year ago | 6019641 |
| 2. | Wellington Management Company LLP | 1 year ago | 4312611 |
| 3. | T. Rowe Price Associates, Inc. | 1 year ago | 2437584 |
| 4. | Rock Springs Capital Management LP | 1 year ago | 2367816 |
| 5. | FMR Inc | 1 year ago | 1696386 |
| 6. | Baker Bros Advisors LP | 1 year ago | 1515318 |
| 7. | General Atlantic Llc | 1 year ago | 1506684 |
| 8. | Paradigm Biocapital Advisors LP | 1 year ago | 1453883 |
| 9. | Bellevue Group AG | 1 year ago | 972254 |
| 10. | Morgan Stanley - Brokerage Accounts | 1 year ago | 917063 |
| 11. | Logos Global Management LP | 1 year ago | 900000 |
| 12. | Fiera Capital Corporation | 1 year ago | 866412 |
| 13. | BlackRock Inc | 1 year ago | 779031 |
| 14. | T. Rowe Price Investment Management,Inc. | 1 year ago | 733611 |
| 15. | Pictet Asset Manangement SA | 1 year ago | 706607 |
| 16. | Bill & Melinda Gates Foundation | 1 year ago | 576923 |
| 17. | COWEN AND COMPANY, LLC | 1 year ago | 536487 |
| 18. | Principal Financial Group Inc | 1 year ago | 517204 |
| 19. | Polar Capital Holdings PLC | 1 year ago | 501300 |
| 20. | TANG CAPITAL MANAGEMENT LLC | 1 year ago | 405600 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...